ストックスクリーナーアプリを入手
2.44
23.86%
0.47
Inflarx Nv (IFRX) 最新ニュース
InflaRx prices $150M stock sale to fund pipeline and working capital - Stock Titan
InflaRx Files Q1 2026 Financials with SEC via Form 6-K - TipRanks
InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares - GlobeNewswire
Funded through 2029, InflaRx expands izicopan into kidney diseases - Stock Titan
InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases - GlobeNewswire
InflaRx (NASDAQ: IFRX) cuts Q1 loss but flags going concern risk - Stock Titan
Top 5 Hot Penny Stocks to Buy Now - Insider Monkey
MSN Money - MSN
InflaRx NV expected to post a loss of 14 cents a shareEarnings Preview - TradingView
InflaRx Highlights Favorable Safety-Signal Data for Izicopan in New Preclinical Study - TipRanks
Low reactive metabolite data support InflaRx (IFRX) oral C5aR1 drug - Stock Titan
InflaRx reports preclinical data on izicopan metabolite formation By Investing.com - Investing.com Australia
In liver lab tests, izicopan showed over 100-fold lower reactive conjugates - Stock Titan
InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes - ChartMill
InflaRx regains Nasdaq compliance after shares trade above $1 - MSN
InfraRX Down Ahead of Next Quarterly Report - Baystreet.ca
IFRX - Finviz
InflaRx N.V. to Publish Q1 2026 Financial Results on May 7, 2026 - Quiver Quantitative
InflaRx to Report First Quarter 2026 Results on May 7, 2026 - ChartMill
InflaRx N.V. (NASDAQ:IFRX) Short Interest Update - MarketBeat
InflaRx (IFRX) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
InflaRx Regains Nasdaq Minimum Bid Price Compliance, Securing Listing Status - TipRanks
InflaRx (Nasdaq: IFRX) back in line with Nasdaq minimum bid price rule - Stock Titan
InflaRx regains Nasdaq minimum bid price compliance By Investing.com - Investing.com Australia
Nasdaq closes InflaRx listing issue after stock holds above $1 - Stock Titan
InflaRx regains Nasdaq minimum bid price compliance - Investing.com
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement - marketscreener.com
InflaRx NV (IFRX) price target decreased by 17.33% to 9.03 - MSN
InflaRx Shareholders Approve Capital, Governance Changes and 2026 Incentive Plan at April AGM - The Globe and Mail
InflaRx (NASDAQ:IFRX) Coverage Initiated at Oppenheimer - MarketBeat
Oppenheimer Adjusts Price Target on InflaRx to $5 From $7, Maintains Outperform Rating - marketscreener.com
InflaRx receives Nasdaq notification - MSN
InflaRx (IFRX) investors back board authorities, article changes and LTIP 2026 - Stock Titan
Guggenheim reiterates Inflarx stock rating on AAV opportunity By Investing.com - Investing.com India
IFRX Reiterated by Guggenheim -- Price Target Maintained at $14 - GuruFocus
InflaRx's (IFRX) "Buy" Rating Reaffirmed at Guggenheim - MarketBeat
InflaRx N.V. (NASDAQ:IFRX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Guggenheim reiterates Inflarx stock rating on AAV opportunity - Investing.com
InflaRx N.V. (IFRX) Stock Mean Reversion (-1.57%) 2026-04-20Community Watchlist - Xã Vĩnh Công
Guggenheim Maintains InflaRx N.V. (IFRX) Buy Recommendation - MSN
IFRX Stock Soars Pre-Market After Experimental Drug Shows Promise In Treating Chronic Skin Diseases - MSN
Is InflaRx N.V. (IFRX) stock gaining bullish momentum (Parabolic) 2026-04-18Open Stock Picks - Xã Châu Thành
0.78%
3.01%
大文字化:
|
ボリューム (24 時間):